Business Context and Reporting Period
This Form 6-K is filed by Can-Fite Biopharma Ltd. for the month of October 2017, dated October 6, 2017. The company is a foreign private issuer based in Petach-Tikva, Israel, focused on the development of product candidates for inflammatory and metabolic diseases.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and does not contain financial statements or quantitative financial data.
Material Changes
The primary material change disclosed is a delay in the commencement of patient enrollment for two key clinical trials:
- Phase III Trial (Piclidenoson): Previously expected to commence in the third quarter of 2017 for the treatment of rheumatoid arthritis; now expected to commence in the fourth quarter of 2017.
- Phase II Trial (Namodenoson): Previously expected to commence in the third quarter of 2017 for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH); now expected to commence in the fourth quarter of 2017.
Guidance, Outlook, and Risks
Management has updated its outlook to reflect the shift of trial start dates to the fourth quarter of 2017. The filing includes a standard special note regarding forward-looking statements, warning that actual results may differ materially due to various risks. Key risks identified include:
- Initiation, timing, progress, and results of preclinical studies and clinical trials.
- Ability to advance product candidates and receive regulatory approvals.
- Market acceptance and commercialization of product candidates.
- Intellectual property protection and potential infringement issues.
- Capital requirements and the need for additional financing.
- Impact of the political and security situation in Israel.
Investor Verification Checklist
- Verify the specific reasons for the delay in patient enrollment for the Piclidenoson and Namodenoson trials.
- Confirm the updated cash runway given the delay in trial milestones and potential impact on capital requirements.
- Review subsequent filings for any further updates on the fourth-quarter enrollment targets.
- Assess the impact of the delay on the company's strategic timeline for regulatory submissions.